148 results

... associated with failure to thrive. Neutropenia is common; thrombocytopenia and anemia are less commonly seen. Autoimmune and/ ... associated with failure to thrive. Neutropenia is common; thrombocytopenia and anemia are also (though less commonly) seen. ...

... to control and reduce the occurrence of infections. Prevention of Primary Manifestations The only curative therapy for ... worsens, rapid transition to HSCT should be considered. Prevention of Secondary Complications The following are appropriate: Use ...

... formal developmental evaluation and intervention before school age. Prevention of Primary Manifestations Prevention of primary manifestations (see ... birth; treatment and monitoring may then start immediately. Prevention of Secondary Complications Prevention or reduction of serious ...

... the current, very effective treatment for viral eradication. Prevention of Primary Manifestations Prophylactic treatment is considered the ... Center (HTC) Directory Centers for Disease Control and Prevention HTC directory Molecular Genetics Information in the Molecular ...

... asymptomatic intracranial aneurysms >10.0 mm in diameter. Prevention of Primary Manifestations Avoidance of anticoagulant exposure and ... trauma may decrease the risk for intracerebral hemorrhage. Prevention of Secondary Complications See Prevention of Primary Manifestations . ...

... examination and (as needed) imaging studies is indicated. Prevention of Primary Manifestations Granulocyte colony-stimulating factor (G- ... dose G-CSF or who undergo malignant transformation. Prevention of Secondary Complications Good dental hygiene with regular ...

... with multisystem disease who have unexplained anemia or thrombocytopenia. The biopsy specimens should be stained with anti- ... nodes, and skin and who present with significant thrombocytopenia (<100,000 × 10 9 /L) and anemia (hemoglobin < ...

... in the peripheral blood, but granulocytopenia, anemia, and thrombocytopenia are also common as proliferating leukemia cells interfere ... 0 × 10 9 /L [1,000/microL]) or thrombocytopenia (<100 × 10 9 /L [100,000/microL]). MLFS ...

... et al [2020] 4. Martinez et al [2016] Prevention of Primary Manifestations To prevent primary manifestations, the ...

... Pierre et al [2008] , Mandia et al [2019] Prevention of Primary Manifestations Early treatment with chenodeoxycholic acid ( ... articles in PubMed Cerebrotendinous xanthomatosis associated with immune thrombocytopenia. [BMJ Case Rep. 2010] Cerebrotendinous xanthomatosis associated with ...